1. Home
  2. SWTX vs HIW Comparison

SWTX vs HIW Comparison

Compare SWTX & HIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWTX
  • HIW
  • Stock Information
  • Founded
  • SWTX 2017
  • HIW 1978
  • Country
  • SWTX United States
  • HIW United States
  • Employees
  • SWTX N/A
  • HIW N/A
  • Industry
  • SWTX Biotechnology: Pharmaceutical Preparations
  • HIW Real Estate Investment Trusts
  • Sector
  • SWTX Health Care
  • HIW Real Estate
  • Exchange
  • SWTX Nasdaq
  • HIW Nasdaq
  • Market Cap
  • SWTX 3.5B
  • HIW 3.1B
  • IPO Year
  • SWTX 2019
  • HIW 1994
  • Fundamental
  • Price
  • SWTX $46.67
  • HIW $30.24
  • Analyst Decision
  • SWTX Buy
  • HIW Buy
  • Analyst Count
  • SWTX 7
  • HIW 6
  • Target Price
  • SWTX $56.86
  • HIW $31.83
  • AVG Volume (30 Days)
  • SWTX 4.9M
  • HIW 921.4K
  • Earning Date
  • SWTX 05-09-2025
  • HIW 07-22-2025
  • Dividend Yield
  • SWTX N/A
  • HIW 6.63%
  • EPS Growth
  • SWTX N/A
  • HIW 32.01
  • EPS
  • SWTX N/A
  • HIW 1.60
  • Revenue
  • SWTX $219,670,000.00
  • HIW $819,789,000.00
  • Revenue This Year
  • SWTX $79.29
  • HIW $0.43
  • Revenue Next Year
  • SWTX $70.79
  • HIW $5.18
  • P/E Ratio
  • SWTX N/A
  • HIW $18.81
  • Revenue Growth
  • SWTX 730.42
  • HIW N/A
  • 52 Week Low
  • SWTX $28.21
  • HIW $24.19
  • 52 Week High
  • SWTX $62.00
  • HIW $36.78
  • Technical
  • Relative Strength Index (RSI)
  • SWTX 60.85
  • HIW 57.68
  • Support Level
  • SWTX $46.21
  • HIW $28.42
  • Resistance Level
  • SWTX $46.77
  • HIW $30.35
  • Average True Range (ATR)
  • SWTX 0.15
  • HIW 0.68
  • MACD
  • SWTX -0.05
  • HIW -0.03
  • Stochastic Oscillator
  • SWTX 85.71
  • HIW 71.65

About SWTX SpringWorks Therapeutics Inc.

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

About HIW Highwoods Properties Inc.

Highwoods Properties Inc is a real estate investment trust engaged in the acquisition, ownership, management, and leasing of properties in urban areas throughout the Southern United States. In terms of total square footage, the vast majority of the company's real estate portfolio comprises office buildings in terms. Highwoods Properties derives nearly all of its income in the form of rental revenue from the tenants of its buildings. The majority of this revenue comes from its holdings in the urban markets of Atlanta, Raleigh, Nashville, and Tampa. These cities also account for the majority of the square footage under the company's ownership. Highwoods Properties customers include the U.S. Government, financial services firms, industrial supply retailers, and healthcare companies.

Share on Social Networks: